Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Klagenfurt

OncologyGrant-onlyListed · DSNKY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: DESTINY Breast Respond HER2-(Ultra)Low Europe

3w agoTrial registeredJun 29, 2026Source filing (opens the source filing in a new tab)

Momentum

88no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Dec 5, 2023
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma · RECRUITING · sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
ClinicalTrials.gov · NCT05993234 (opens the source filing in a new tab)
Trial
Study registered
Oct 24, 2023
Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer · RECRUITING · sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · DESTINY Breast Respond HER2-(Ultra)Low Europe
ClinicalTrials.gov · NCT05945732 (opens the source filing in a new tab)
Trial
Study registered
Jan 15, 2021
Hypercholesterolemia, Mixed Dyslipidemia · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
ClinicalTrials.gov · NCT04579367 (opens the source filing in a new tab)
Trial
Study registered
Apr 6, 2016
Venous Thromboembolism · COMPLETED · sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
ClinicalTrials.gov · NCT02943993 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.97name similarity 100% · semantic similarity 80% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
new_entity links the trial record at 0.50shared principal investigator / founder · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: DESTINY Breast Respond HER2-(Ultra)Low Europe
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: DESTINY Breast Respond HER2-(Ultra)Low Europe
3w agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
4mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
Apr 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources